Moderna’s COVID-19 Vaccine Candidate Shows Hopeful Results Of Efficacy And Safety.
Results from an early safety study of Moderna’s COVID-19 vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those seen in younger adults, with side effects that are about the same with high-dose flu shots.
At first, a Phase I safety trial was conducted in individuals aged 18-55 but extended to test two doses of vaccine, 25 micrograms, and 100 micrograms respectively in 40 adults aged 56 to 70 and 71 and older after there were findings that vaccine immunity decreases with age.
Moderna is also already testing a higher dosage in a large Phase III trial.
The study was published in the New England Journal of Medicine.
Serum Institute of India To Boost Its COVID-19 vaccine production of up to 200 million doses.
Serum Institute of India recently announced that they will be ramping up its vaccine production to up to 200 million COVID-19 vaccine doses for poorer countries as Bill & Melinda Gates Foundation and GAVI vaccines alliance have increased their funding by twice fold.
The additional funds will help in boosting the manufacturing of the vaccine candidates from AstraZeneca and Novavax for delivery under the COVAX scheme as early as the first half of 2021.
The COVAX scheme, co-led by the World Health Organization (WHO) and GAVI, aims to deliver 2 billion vaccine doses around the world by the end of 2021.
A study shows potential for HPV vaccine to be effective against cervical cancer.
A study by a large group of researchers from Karolinska Institutet shows that women vaccinated against HPV have a significantly lower risk of developing cervical cancer, and the positive effect is most pronounced for women vaccinated at a young age.
In this study, the researchers for 11 years followed almost 1.7 million women between the ages of 10 and 30. Of those women, more than 500,000 were vaccinated against HPV, the majority before the age of 17. Nineteen vaccinated women were diagnosed with cervical cancer compared to 538 unvaccinated women, corresponding to 47 and 94 women per 100,000, respectively.
The researchers’ analysis shows that HPV vaccination was linked to a significantly reduced risk of cervical cancer and that girls vaccinated before age 17 reduced their risk of cervical cancer by 88 percent. Women vaccinated between ages 17 and 30 halved their risk of cervical cancer compared to unvaccinated women, according to the study. The study was published in the New England Journal of Medicine.